Mankind Pharma , a leading pharmaceutical company in India, has reiterated its commitment to achieving strong financial performance targets for the fiscal year 2026 (FY26). The company's management has confirmed that they remain on track to meet their ambitious margin goals, while also making strides in expanding their global footprint.

Margin Targets Remain Steady

Mankind Pharma's management has reaffirmed their confidence in achieving the following financial targets for FY26:

These targets underscore the company's focus on operational efficiency and profitability in the coming years.

Global Expansion Plans

In a significant development for the company's international growth strategy, Mankind Pharma expects to receive approvals for dydrogesterone from global markets by the end of 2025. Dydrogesterone is a hormone medication used in various treatments, including hormone replacement therapy and certain pregnancy-related conditions.

The anticipated global approvals could potentially open up new markets for Mankind Pharma, enhancing its international presence and revenue streams.

Recent Financial Performance

While specific financial figures for the most recent quarter were not provided, it's worth noting that Mankind Pharma has been actively engaging with investors. The company recently held an investor conference call for Q1 FY26 on August 1, 2025, demonstrating its commitment to transparency and shareholder communication.

Looking Ahead

As Mankind Pharma works towards its FY26 goals, the company appears to be balancing its focus between maintaining strong domestic performance and expanding its global reach. The potential approval of dydrogesterone in international markets by late 2025 could serve as a significant milestone in the company's growth trajectory.

Investors and industry observers will likely be keeping a close eye on Mankind Pharma's progress towards these targets and its success in penetrating new global markets with key products like dydrogesterone.

Note: This article is based on the latest available information as of August 1, 2025. Investors are advised to conduct their own research and consult financial advisors before making investment decisions.

Mankind Pharma , India's fourth-largest pharmaceutical company, has announced its financial results for the first quarter, showcasing strong revenue growth but a decline in profits. The company's performance reflects its continued market expansion and challenges in maintaining profitability.

Revenue Surge

Mankind Pharma reported a consolidated revenue of ₹3,570.00 crore for Q1, marking a significant 24.5% increase compared to ₹2,868.00 crore in the same period last year. This robust growth was primarily driven by strong performance in both domestic and export markets.

Domestic Market Performance

The company's domestic revenue grew by 18.9% year-over-year, reaching ₹3,101.00 crore. This growth was supported by:

• Outperformance in chronic therapies, with 1.4x growth compared to the Indian Pharmaceutical Market (IPM)
• Strong growth in the consumer healthcare segment
• Consolidation of Bharat Serums and Vaccines Limited (BSV)

Mankind Pharma's market share in the domestic market increased from 4.8% in March to 4.9% in June, indicating continued market penetration.

Export Business

The export business showed remarkable growth, with revenue increasing by 81.1% year-over-year to ₹469.00 crore. This surge was attributed to the consolidation of BSV and growth in the base business.

Profit Decline

Despite the strong revenue growth, Mankind Pharma experienced a decline in profitability:

• Net profit decreased by 17.4% to ₹445.00 crore, compared to ₹538.00 crore in the same quarter of the previous year
• EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) margin stood at 23.8%, a slight improvement of 20 basis points year-over-year

Key Highlights

• Consumer healthcare revenue grew by 15% year-over-year to ₹237.00 crore
• The company maintained its #1 rank in prescriptions over the last eight years
• Chronic segment share increased to 37.1% of the total portfolio
• Mankind Pharma launched one product in the US market during Q1, bringing the total launched products to 45

Management Commentary

Mr. Rajeev Juneja, Vice Chairman & Managing Director of Mankind Pharma, stated, "Mankind's revenue grew by 24.5% with EBITDA margins at 23.8% in Q1 led by continued 1.4x outperformance in Chronic, strong growth in Consumer segment and BSV consolidation. Visible encouraging trends with 1.8x volume growth to IPM led by outperformance in Anti-infectives & Respiratory segment – apart from continued outperformance in Cardiology and Anti Diabetics."

Dividend Announcement

To mark the company's 30th year of operations, the Board of Directors has approved an interim dividend of ₹1.00 per share.

Conclusion

Mankind Pharma's Q1 results demonstrate the company's ability to drive revenue growth across its business segments. However, the decline in profitability suggests challenges in managing costs and maintaining margins. The company's focus on chronic therapies, consumer healthcare, and export markets continues to be key drivers of its growth strategy.